STOCK TITAN

Pulmatrix, Inc. - PULM STOCK NEWS

Welcome to our dedicated page for Pulmatrix news (Ticker: PULM), a resource for investors and traders seeking the latest updates and insights on Pulmatrix stock.

Pulmatrix, Inc. (NASDAQ: PULM) is a clinical-stage biopharmaceutical company dedicated to developing innovative inhaled therapies to treat serious pulmonary and central nervous system (CNS) diseases using its proprietary dry powder inhalation technology, iSPERSE™. iSPERSE™ stands for Inhaled Small Particles Easily Respirable and Emitted—an advanced dry powder drug delivery platform that allows a broad range of drugs to be formulated as small, dense, and dispersible particles for efficient delivery and deep lung penetration.

Pulmatrix's product pipeline includes treatments for various respiratory conditions such as Allergic Bronchopulmonary Aspergillosis (ABPA) and Chronic Obstructive Pulmonary Disease (COPD), as well as CNS disorders such as acute migraine. Their lead product candidate, PUR1900, is an orally inhaled dry powder formulation of itraconazole designed to treat ABPA. This formulation aims to reduce systemic side effects by maximizing local lung concentrations.

Another promising candidate is PUR3100, an orally inhaled formulation of dihydroergotamine (DHE) for the treatment of acute migraine. The Phase 1 study demonstrated PUR3100's potential for rapid pain relief and improved tolerability compared to intravenous DHE. Pulmatrix plans to advance PUR3100 into a Phase 2 clinical trial.

Financially, Pulmatrix has maintained operational efficiency with a cash runway into Q1 2026, primarily owing to cost-saving measures such as stopping patient enrollment in the Phase 2b study of PUR1900 and focusing on strategic alternatives. The company recently announced a significant partnership with MannKind Corporation, which includes a cross-licensing agreement for the iSPERSE™ technology and the assumption of Pulmatrix’s R&D facility lease.

For more information on Pulmatrix's innovative inhaled product candidates, please visit their pipeline page.

Rhea-AI Summary
Results show low likelihood of drug-drug interactions with PUR1900, potentially making it a safer alternative to oral itraconazole therapy for ABPA patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.61%
Tags
none
-
Rhea-AI Summary
Pulmatrix, Inc. announces Q2 2023 financial results and corporate update. Enrollment for Phase 2b study of PUR1900 ongoing with 13 active sites. IND submitted for Phase 2 study of PUR3100 for Acute Migraine. $25.8 million in cash and cash equivalents at end of Q2 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.38%
Tags
-
Rhea-AI Summary
Pulmatrix has submitted an IND application to the FDA for PUR3100, an inhaled dry powder formulation of dihydroergotamine (DHE) to treat acute migraine. The Phase 1 study showed that PUR3100 had similar pharmacokinetics to IV DHE with fewer side effects.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.75%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.21%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.1%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.79%
Tags
News
Rhea-AI Summary
Pulmatrix announces support for World Asthma Day and ongoing clinical trial for PUR1900. PUR1900 has potential to be first approved treatment for ABPA.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.4%
Tags
none
-
Rhea-AI Summary

Pulmatrix, Inc. (NASDAQ: PULM) announced its 2022 financial results and corporate updates on March 30, 2023. The company reported revenue of $6.1 million, a 17% increase from $5.2 million in 2021, driven by collaborations. The year-end cash position stood at $35.6 million, providing a runway into Q2 2024. Significant milestones include the initiation of a Phase 2b study for PUR1900, with the first patient dosed in Q1 2023, and successful topline results for the Phase 1 study of PUR3100, showing promising safety and efficacy data. The company aims for further clinical studies for both PUR1900 and PUR3100.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.77%
Tags
none
-
Rhea-AI Summary

Pulmatrix, Inc. (NASDAQ: PULM) announced the dosing of the first patient in a Phase 2b clinical trial for PUR1900, an inhaled treatment for Allergic Bronchopulmonary Aspergillosis (ABPA) and asthma. This double-blind, placebo-controlled study will assess the safety and efficacy of PUR1900 over 16 weeks, followed by an 8-week observation period. The trial aims to enroll 30 subjects across the U.S., U.K., Australia, and France. This milestone supports Pulmatrix's collaboration with Cipla and targets proof-of-concept data by mid-2024, potentially establishing PUR1900 as the first approved treatment for ABPA.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.28%
Tags
Rhea-AI Summary

Pulmatrix, Inc. (NASDAQ: PULM) announces a virtual key opinion leader (KOL) event titled "PUR3100 for the Treatment of Acute Migraine: Unlocking Potential of DHE Treatment" on February 3, 2023, at 10:00 AM ET. The event features Dr. Stewart J. Tepper from Dartmouth College, discussing the treatment landscape for migraine patients and the clinical profile of dihydroergotamine (DHE). Dr. Margaret Wasilewski, CMO of Pulmatrix, will present recent Phase 1 data on PUR3100, an orally inhaled DHE delivered via Pulmatrix's patented iSPERSE™ technology. The event will include a live Q&A session.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.16%
Tags
conferences

FAQ

What is the current stock price of Pulmatrix (PULM)?

The current stock price of Pulmatrix (PULM) is $5.76 as of December 23, 2024.

What is the market cap of Pulmatrix (PULM)?

The market cap of Pulmatrix (PULM) is approximately 21.2M.

What is iSPERSE™ technology?

iSPERSE™ is Pulmatrix's proprietary dry powder inhalation technology designed for efficient drug delivery and deep lung penetration.

What diseases is Pulmatrix targeting with its therapies?

Pulmatrix is developing treatments for respiratory diseases like ABPA and COPD, as well as CNS disorders such as acute migraine.

What is PUR1900?

PUR1900 is an orally inhaled dry powder formulation of itraconazole, designed to treat Allergic Bronchopulmonary Aspergillosis (ABPA).

How does PUR3100 help with migraines?

PUR3100 is an inhaled formulation of dihydroergotamine (DHE) for acute migraine treatment, offering rapid pain relief and improved tolerability.

What recent partnerships has Pulmatrix announced?

Pulmatrix recently entered into a cross-licensing agreement with MannKind Corporation, which includes developing iSPERSE™-formulated therapies.

What are Pulmatrix's financial prospects?

Pulmatrix has a robust cash position with operational efficiencies expected to fund operations into Q1 2026.

Where can I find more information about Pulmatrix's products?

You can visit Pulmatrix's pipeline page at https://www.pulmatrix.com/pipeline.html for detailed information on their product candidates.

What is the focus of Pulmatrix’s clinical trials?

Pulmatrix’s clinical trials focus on advancing PUR1900 for ABPA and PUR3100 for acute migraine into Phase 2 studies.

Who are the key executives at Pulmatrix?

Key executives include Ted Raad, the Chief Executive Officer, and Dr. Margaret Wasilewski, the Chief Medical Officer.

How does Pulmatrix aim to address unmet medical needs?

Pulmatrix aims to address unmet medical needs by developing inhaled therapies that offer improved delivery and reduced side effects using its iSPERSE™ technology.

Pulmatrix, Inc.

Nasdaq:PULM

PULM Rankings

PULM Stock Data

21.18M
3.65M
0%
7.16%
0.18%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
FRAMINGHAM